Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102565 | 1.00 | GABRR1 (0.32) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL8197140 | 1.00 | GABRR1 (0.32) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL506328 | 0.89 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL6476 | 0.88 | GABRR1 (0.34) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL3102587 | 0.88 | GABRR1 (0.34) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL2273461 | 0.88 | GABRR1 (0.34) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL6017 | 0.88 | GABRR1 (0.34) | GABRR1GABRR2PLGPLATLMNA | |
| SCHEMBL860060 | 0.81 | RIPK1 (0.33) | LMNARIPK1 | |
| SCHEMBL3058485 | 0.81 | RIPK1 (0.32) | LMNARIPK1DPP4 | |
| SCHEMBL791000 | 0.81 | RIPK1 (0.33) | LMNARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| US-8318742-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8063070-B2 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-11-22 | — | — | US | disclosed |
| EP-2305254-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions | Janssen Pharmaceutica NV (BE) | 2011-04-06 | — | — | EP | disclosed |
| US-7790750-B2 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-7652040-B2 | gastrointestinal disorders hypermotility, irritable bowel syndrome, constipation or diarrhea | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7638535-B2 | (3S)-trans)-8-methyl-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid [3-hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide; hypermotility, irritable bowel syndrome, constipation or diarrhea predominant IDS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A | 2007-02-15 | — | — | US | disclosed |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142339-A1 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht 4-antagonists | HTR4, HTR2B, HTR2C | GABRR1 638/4885GABRR2 538/4885PLG 2378/4885 |
| US-20070037850-A1 | used for the prophylaxis and therapeutic treatment of conditions involving decreased gastrointestinal motility, in particular decreased gastric emptying; gastrointestinal disorders | HRH2, HRH4, GIPR | GABRR1 36/4885GABRR2 55/4885PLG 3498/4885 |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | HTR4, HTR2B, HTR5A | GABRR1 494/4885GABRR2 435/4885PLG 2746/4885 |
| US-20120028987-A1 | Bicyclic Benzamides of 3-Or-4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, SLC10A2, HRH4 | GABRR1 422/4885GABRR2 414/4885PLG 1766/4885 |
| US-20060281753-A1 | 4-(Aminomethyl)-piperidine benzamides as 5ht4 - antagonists | HTR4, HTR2B, HTR5A | GABRR1 462/4885GABRR2 415/4885PLG 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.